Rituximab during pregnancy in neuromyelitis optica: A case report

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disorder of the CNS, which predominantly targets the optic nerves and spinal cord leading to blindness and paralysis.1 There is a 6–9:1 ratio affecting females far more often than males, and there is an increased risk of relapse during and immediately after pregnancy.2 B-cell depletion therapy has been reported to prevent rebound in postpartum relapses.3,4 In this report, we describe the safety and clinical effect of B-cell depletion in both the patient and her infant baby.